Bezisterim Shows Motor and Non-Motor Gains in Inflammatory Parkinson's Subgroup
BIVI sits 70% above its 52-week low of $0.82.
Summary
BioVie released detailed Phase 2 SUNRISE-PD data showing bezisterim beat placebo in early Parkinson's patients with above-median platelet counts, a prespecified inflammatory subgroup. Non-motor scores improved -1.62 vs +1.86 (p=0.0124), motor scores -1.32 vs +1.26 (p=0.0265), and the total score -1.23 vs +1.21 (p=0.0006). The Composite Benefit Score showed a large effect (d=-1.61), with 25% of treated patients achieving meaningful improvement versus 4% on placebo, and safety matched placebo over 12 weeks with no serious adverse events. This builds on the August 6 8-K that first disclosed positive SUNRISE-PD results, adding the biomarker-defined subgroup detail that could shape Phase 3 design. The company still carries a going concern warning, a $22.1M annual loss, and heavy dilution headroom, so the data must translate into a funded Phase 3 to matter. Watch for regulatory alignment on endpoints and a Phase 3 plan.
At the time of this announcement, BIVI was trading at $1.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.7M. The 52-week trading range was $0.82 to $3.79. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.